Educational Risk Minimisation Materials to help reduce the risk associated with using Waylivra (volanesorsen sodium)

Waylivra is very commonly linked to reductions in platelet count in patients with familial chylomicronemia syndrome, which may result in thrombocytopenia. Guide for Healthcare Professionals and Patient and Carer Guide provides info on monitoring and treatment adjustment if needed

Akcea Therapeutics UK Ltd